脊柱关节炎患者免疫应答谱揭示TNF阻断剂体内信号网络机制
该研究对80例中轴型脊柱关节炎患者TNFi治疗前后的外周血进行标准化全血刺激和基因表达分析,发现抗TNF治疗主要改变固有免疫应答,选择性影响多条信号通路,且治疗前白细胞黏附、趋化及IL-1信号相关分子表达与疗效相关。
要点
- 抗TNF治疗显著改变SpA患者固有免疫应答,对Th1/Th17免疫影响较小。
- TNFi体内靶向前列腺素E2合成与信号、白细胞再循环、巨噬细胞极化等通路。
- 治疗前白细胞黏附、侵袭、趋化及IL-1信号分子表达与TNFi疗效相关。
核心结论
- TNFi靶向多个协同解决炎症的免疫细胞通路,免疫应答谱可识别与生物制剂疗效相关的信号通路。
研究设计与样本
- 研究纳入80例中轴型脊柱关节炎患者,在TNFi治疗前后采集外周血,采用高度标准化的全血刺激试验分析对微生物及通路特异性刺激的免疫应答。
主要发现
- 抗TNF治疗诱导患者固有免疫应答发生深刻变化,对Th1/Th17免疫仅有轻微影响。
- 模块化转录组分析识别出前列腺素E2合成与信号、白细胞再循环、巨噬细胞极化、dectin和IL-1信号以及NF-κB转录因子家族为TNF阻断剂体内靶向的关键通路。
- 治疗前诱导免疫应答分析显示,白细胞黏附与侵袭、趋化及IL-1信号相关分子的表达与抗TNF治疗反应相关。
临床怎么用
- 治疗前免疫应答谱可能用于识别对TNFi有反应的患者,并揭示与生物制剂疗效相关的信号通路。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Antitumour necrosis factor (TNF) therapy has revolutionised treatment of several chronic inflammatory diseases, including spondyloarthritis (SpA). However, TNF inhibitors (TNFi) are not effective in all patients and the biological basis for treatment failure remains unknown. We have analysed induced immune responses to define the mechanism of action of TNF blockers in SpA and to identify immunological correlates of responsiveness to TNFi. METHODS: Immune responses to microbial and pathway-specific stimuli were analysed in peripheral blood samples from 80 patients with axial SpA before and after TNFi treatment, using highly standardised whole-blood stimulation assays. Cytokines and chemokines were measured in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory, and gene expression was monitored using nCounter assays. RESULTS: Anti-TNF therapy induced profound changes in patients' innate immune responses. TNFi action was selective, and had only minor effects on Th1/Th17 immunity. Modular transcriptional repertoire analysis identified prostaglandin E2 synthesis and signalling, leucocyte recirculation, macrophage polarisation, dectin and interleukin (IL)-1 signalling, as well as the nuclear factor kappa B (NF-kB) transcription factor family as key pathways targeted by TNF blockers in vivo. Analysis of induced immune responses before treatment initiation revealed that expression of molecules associated with leucocyte adhesion and invasion, chemotaxis and IL-1 signalling are correlated with therapeutic responses to anti-TNF. CONCLUSIONS: We show that TNFi target multiple immune cell pathways that cooperate to resolve inflammation. We propose that immune response profiling provides new insight into the biology of TNF-blocker action in patients and can identify signalling pathways associated with therapeutic responses to biological therapies.
引用
- Menegatti S, Guillemot V, Latis E, et al. Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo. Ann Rheum Dis. 2020. PMID: 33268443. doi:10.1136/annrheumdis-2020-218304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。